biote Corp.
NASDAQ:BTMD · NASDAQ Global Market
+$0.03 today
Vol 0.20M · Avg 0.27M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:BTMD · Revenue to Net Income
Key Ratios
Analysis
$188.2M of revenue converted into $15.6M of net income for the selected period. Gross margin is 68.4% and net margin is 8.2%, showing how much revenue survives after costs and taxes. EPS is $0.45, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $192.2M -2.5% | $197.2M +6.4% | $185.4M +12.4% | $165.0M +18.3% | $139.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $58.1M -0.0% | $58.1M +0.4% | $57.9M +6.1% | $54.6M +11.8% | $48.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $134.1M -3.6% | $139.1M +9.1% | $127.5M +15.5% | $110.4M +21.9% | $90.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 69.8% -0.8pp | 70.5% +1.7pp | 68.8% +1.9pp | 66.9% +1.9pp | 65.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $95.0M -11.6% | $107.5M +8.7% | $98.8M -42.2% | $171.1M +217.1% | $54.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $95.0M -11.6% | $107.5M +8.7% | $98.8M -42.2% | $171.1M +205.4% | $56.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.7M +2.7% | $3.6M +350.1% | $794.0K -63.9% | $2.2M +57.1% | $1.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | $53.1M +240.7% | $15.6M -60.6% | $39.5M +396.8% | $8.0M -77.9% | $36.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 27.6% +19.7pp | 7.9% -13.4pp | 21.3% +16.5pp | 4.8% -21.0pp | 25.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $39.1M +23.8% | $31.6M +10.3% | $28.7M +147.2% | -$60.7M -275.7% | $34.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 20.4% +4.3pp | 16.0% +0.6pp | 15.5% +52.3pp | -36.8% -61.6pp | 24.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $900.0K | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $11.9M +7.8% | $11.0M +72.9% | $6.4M +57.2% | $4.0M +141.9% | $1.7M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.5M +95.0% | -$30.6M -6.3% | -$28.8M -146.1% | $62.4M +3870.2% | -$1.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $37.6M +3599.2% | $1.0M +926.0% | -$123.0K -107.2% | $1.7M -94.8% | $32.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 19.6% +19.0pp | 0.5% +0.6pp | -0.1% -1.1pp | 1.0% -22.6pp | 23.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $6.0M +517.2% | $970.0K -63.8% | $2.7M +591.2% | $388.0K +35.7% | $286.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $27.0M +756.7% | $3.2M -4.8% | $3.3M +442.2% | -$969.0K -103.0% | $32.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 14.1% +12.5pp | 1.6% -0.2pp | 1.8% +2.4pp | -0.6% -24.0pp | 23.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +833.8% | $0 -29.2% | $0 -18.8% | $0 +118.4% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +703.5% | $0 -29.2% | $0 -18.8% | $0 +118.4% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $31.3M -8.7% | $34.3M +33.3% | $25.7M +219.0% | $8.1M +6.4% | $7.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $36.7M +7.0% | $34.3M +33.3% | $25.7M +219.0% | $8.1M +6.4% | $7.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Anika Therapeutics, Inc.
NASDAQ:ANIK
$195.86M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
The Joint Corp.
NASDAQ:JYNT
$136.57M
Vor Biopharma Inc.
NASDAQ:VOR
$98.42M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Scilex Holding Company
NASDAQ:SCLX
$72.18M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Actuate Therapeutics Inc
ACTU
$48.33M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BTMD generate?
biote Corp. (BTMD) reported $192.22M of revenue in fiscal 2025.
Is BTMD profitable?
biote Corp. (BTMD) reported $27.05M of net income, with a net margin of 14.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.